Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects
← catalyst calendarSponsored by Biodesix, Inc. (industry) · BDSX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
5,006actual
Sites
42
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2016-04-04 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2017-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Primary outcome
what the primary-completion date above is the date OFPhysician Treatment Patterns Description
measured 3 years
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2017-09-18 · 1.1 MB · Prot_003.pdf
Informed Consent Formposted 2017-09-18 · 334 KB · ICF_002.pdf
Publications
- PMID 28277859 — cited as background
- PMID 27898657 — cited as background
- PMID 34706885 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BDSX's whole pipeline · Catalyst calendar · Every registered study · What changed